A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-α related activity level by more than 30% comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition.

The present invention relates to biocidal agents designed to protect industrial products against microbial, bacterial, fungal and algal infections. In particular, the present invention relates to co-crystals containing 3-iodopropynyl butylcarbamate (IPBC) and to compositions containing said co-crystals which possess improved physical, chemical and workability properties compared with the use of IPBC.

The present invention relates to biocidal agents designed to protect industrial products against microbial, bacterial, fungal and algal infections. In particular, the present invention relates to co-crystals containing 3-iodopropynyl butylcarbamate (IPBC) and to compositions containing said co-crystals which possess improved physical, chemical and workability properties compared with the use of IPBC.

Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.

Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.

Disclosed is a solid arthropodicide composition comprising by weight (a) from 0.3 to 100% of a particulate component comprising particles of a solid carrier infiltrated with a mixture comprising (i) one or more carboxamide arthropodicides and (ii) a surfactant constituent; (b) from 0 to 50% of a surfactant component having dispersing and wetting properties; and (c) from 0 to 99.7% of one or more additional formulating ingredients.
Also disclosed is a propagule contacted with a biologically effective amount of said composition.

Disclosed is a solid arthropodicide composition comprising by weight (a) from 0.3 to 100% of a particulate component comprising particles of a solid carrier infiltrated with a mixture comprising (i) one or more carboxamide arthropodicides and (ii) a surfactant constituent; (b) from 0 to 50% of a surfactant component having dispersing and wetting properties; and (c) from 0 to 99.7% of one or more additional formulating ingredients.
Also disclosed is a propagule contacted with a biologically effective amount of said composition.

Polymeric particles are provided that have pores (i.e., free volume or voids). The polymeric particles can be used to store or deliver active agents that are adsorbed in the pores of the polymeric particles. In many embodiments, the active agents are hydrophobic. Reaction mixtures and methods of forming the polymeric particles from the reaction mixtures are also provided.

Polymeric particles are provided that have pores (i.e., free volume or voids). The polymeric particles can be used to store or deliver active agents that are adsorbed in the pores of the polymeric particles. In many embodiments, the active agents are hydrophobic. Reaction mixtures and methods of forming the polymeric particles from the reaction mixtures are also provided.

Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.